Haemostatic effect of adding tranexamic acid to emicizumab prophylaxis in severe haemophilia A: A preclinical study.

Maissa JanbainNathalie EnjolrasRadu BolbosMarie BrevetJean-Claude BordetDargaud Yesim

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2021)

Our results suggest a potential benefit of TxAc when used in combination with emicizumab in prophylactic settings, especially in patients presenting breakthrough bleeds.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
case report
mesenchymal stem cells
risk assessment
human health
drug induced